The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery

Bone tumor surgery is associated with a significant risk of intraoperative blood loss and transfusion, with blood loss usually in the range of approximately 500-1000 ml and an average transfusion of up to 2 units of allogeneic red blood cell. The increase in allogeneic blood transfusion volume is an independent risk factor for postoperative complications in patients undergoing bone tumor surgery, as well as affecting the long-term survival rate of cancer patients.

Acute normovolemic hemodilution (ANH) is a patient blood management measure. The clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial. It is of great importance to explore the efficacy of ANH in bone cancer surgery patients.

Bone cancer surgery is an ideal setting to evaluate the efficacy of ANH, as the procedure is associated with high blood loss and infusion. The 'Hemodilution on intraoperative Allogeneic Transfusion' (HEAL) trial has been designed as a randomized, controlled trial to determine whether ANH will reduce the volume of intraoperative allogeneic red blood cell transfusion in patients undergoing bone cancer surgery.

Inclusion criteria

• age 18 to 75 years;
• undergoing elective bone tumor resection surgery;
• preoperative hemoglobin ≥11 g/dL;

Exclusion criteria

• using a tourniquet;
• palliative operation or minimally invasive surgery;
• BMI<18.5 or >30Kg/m^2;
• international normalized ratio (INR) >1.5 or platelet count <100 × 10^9/L;
• cardiopulmonary insufficiency;
• hepatic and renal dysfunction;
• active infectious disease;
• allergy to succinyl gelatin;
• pregnancy;
• declined participation in the study or declined blood transfusion